Form 4: Edgewise Therapeutics Executive Awarded Stock Options and Restricted Stock Units
SEC Form 4
Marc Semigran, Chief Development Officer of Edgewise Therapeutics, receives stock options and restricted stock units as part of compensation.
Summary
- On August 12, 2024, Marc Semigran, the Chief Development Officer of Edgewise Therapeutics, Inc., was granted stock options to purchase 138,750 shares of common stock at an exercise price of $17.05.
- These options vest monthly over 48 months starting August 12, 2024, contingent upon continued service.
- Semigran also received 23,125 restricted stock units (RSUs), each representing a right to receive one share of Edgewise Therapeutics common stock.
- The RSUs vest in four equal annual installments beginning August 12, 2024.
Sentiment
Score: 7
Explanation: The document reflects standard executive compensation practices, which is generally viewed neutrally to positively as it incentivizes management. There are no immediate negative implications.
Positives
- The grant of stock options and RSUs aligns the executive's interests with those of the shareholders.
- Vesting schedules incentivize continued service and contribution to the company's success.
Future Outlook
The vesting of stock options and RSUs is contingent upon the reporting person's continued service as a provider.
Industry Context
Granting stock options and RSUs is a common practice in the biotechnology industry to attract, retain, and incentivize key executives.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry, often benchmarked against peer companies of similar size and stage of development.
- Companies like Sarepta Therapeutics and BioMarin Pharmaceutical also utilize stock options and RSUs to incentivize their executives.
- The vesting schedules are typical, aligning with industry norms to encourage long-term commitment.
Stakeholder Impact
- Shareholders may view the grants positively as they align executive interests with company performance.
- Employees may see it as a positive sign of investment in leadership.
Key Dates
| Date | Description |
|---|---|
| 08/12/2024 | Date of transaction: Grant of stock options and restricted stock units. |
| 08/12/2024 | Start date for monthly vesting of stock options (1/48th per month). |
| 08/12/2024 | Start date for annual vesting of restricted stock units (1/4th per year). |
| 08/12/2034 | Expiration date of the stock options. |
| 08/14/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.